Kalaris Therapeutics, Inc. (KLRS)

NASDAQ

$2.06

$-0.01

(-0.34%)

Pre-Market

Kalaris Therapeutics, Inc. (KLRS) Live Price Chart

Last updated: ⁦2026-10-21 12:45:20⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Kalaris Therapeutics, Inc. (KLRS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.06, with a market capitalization of $45.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.87 to $11.88. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$45.47M
Open	$2.07
Day's High	$12.90
Day's Low	$1.87
Previous Close	$2.07
Volume	1.00
Average Volume	75.60K
P/E Ratio	--
52-Week High	$11.88
52-Week Low	$1.87
Dividend Yield	--
Earnings Date	--

Kalaris Therapeutics, Inc. (KLRS) Pre-Market Stock Price

Kalaris Therapeutics, Inc. (KLRS) is trading at $2.06 in pre-market trading as of 2026-10-21 11:57:00, down 0.43% ($0.01) from the previous close of $2.07

Pre-market trading shows how investors are pricing KLRS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.

Kalaris Therapeutics, Inc. (KLRS) 7-Day Stock Price Change

Over the past seven days, Kalaris Therapeutics, Inc. (KLRS) moved from $2.26 to $2.06, representing a decline of 8.81% ($0.20).

The stock traded between $1.87 and $2.37 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.

The average daily volume was 93.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

KLRS 52-Week Price Position

Position in Range: 1.9%

52W Low$1.87

52W High$11.88

KLRS is currently trading at $2.06, placing it 1.9% of the way from its 52-week low of $1.87 to its 52-week high of $11.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Kalaris Therapeutics, Inc. (KLRS)?

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Kalaris Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	20
Exchange	NASDAQ
Company Website	https://www.kalaristx.com

How to Buy Kalaris Therapeutics, Inc. (KLRS) Stock on MEXC

Eligible investors can buy real shares of Kalaris Therapeutics, Inc. (KLRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for KLRS and Place Your Order

Open the RealStocks trading page and search for KLRS. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Kalaris Therapeutics, Inc. (KLRS) stock price today?

Kalaris Therapeutics, Inc. (KLRS) is currently trading at $ 2.06, down 0.43% ($0.01) from the previous close of $ 2.07. Intraday prices update in real time during regular trading hours.

2.Is KLRS stock going up or down today?

As of 2026-10-21 11:57:00, KLRS is trading at $ 2.06, down 0.43% ($0.01) from its previous close of $ 2.07. The stock has traded between $ 1.87 and $ 12.90 during today’s regular session. Past price movements do not guarantee future results.

3.What is KLRS pre-market price?

As of 2026-10-21 11:57:00, KLRS is trading at $ 2.06 in pre-market trading, down 0.43% ($0.01) from the previous close of $ 2.07. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is KLRS after-hours price?

As of 2026-10-21 11:57:00, KLRS is trading at $ 2.07 in after-hours trading, unchanged from the regular-session close of $ 2.07. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is KLRS stock trading now?

KLRS trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does KLRS sit relative to its 52-week high and low?

Over the past 52 weeks, KLRS has traded between a low of $ 1.87 and a high of $ 11.88. At $ 2.06, the stock is positioned 1.9% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Kalaris Therapeutics, Inc. in?

Kalaris Therapeutics, Inc. (KLRS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Kalaris Therapeutics, Inc.'s market capitalization and where is it listed?

Kalaris Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $ 45.47M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is KLRS valued in terms of P/E ratio and EPS?

KLRS trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -1.86. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Kalaris Therapeutics, Inc. pay a dividend?

Kalaris Therapeutics, Inc. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.